Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. / Bach, Anders; Clausen, Bettina H; Kristensen, Lotte K; Andersen, Maria G; Ellman, Ditte Gry; Hansen, Pernille B L; Hasseldam, Henrik; Heitz, Marc; Özcelik, Dennis; Tuck, Ellie J; Kopanitsa, Maksym V; Grant, Seth G N; Lykke-Hartmann, Karin; Johansen, Flemming F; Lambertsen, Kate L; Strømgaard, Kristian.

In: Neuropharmacology, Vol. 150, 02.03.2019, p. 100-111.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bach, A, Clausen, BH, Kristensen, LK, Andersen, MG, Ellman, DG, Hansen, PBL, Hasseldam, H, Heitz, M, Özcelik, D, Tuck, EJ, Kopanitsa, MV, Grant, SGN, Lykke-Hartmann, K, Johansen, FF, Lambertsen, KL & Strømgaard, K 2019, 'Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor', Neuropharmacology, vol. 150, pp. 100-111. https://doi.org/10.1016/j.neuropharm.2019.02.035

APA

Bach, A., Clausen, B. H., Kristensen, L. K., Andersen, M. G., Ellman, D. G., Hansen, P. B. L., ... Strømgaard, K. (2019). Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. Neuropharmacology, 150, 100-111. https://doi.org/10.1016/j.neuropharm.2019.02.035

Vancouver

Bach A, Clausen BH, Kristensen LK, Andersen MG, Ellman DG, Hansen PBL et al. Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. Neuropharmacology. 2019 Mar 2;150:100-111. https://doi.org/10.1016/j.neuropharm.2019.02.035

Author

Bach, Anders ; Clausen, Bettina H ; Kristensen, Lotte K ; Andersen, Maria G ; Ellman, Ditte Gry ; Hansen, Pernille B L ; Hasseldam, Henrik ; Heitz, Marc ; Özcelik, Dennis ; Tuck, Ellie J ; Kopanitsa, Maksym V ; Grant, Seth G N ; Lykke-Hartmann, Karin ; Johansen, Flemming F ; Lambertsen, Kate L ; Strømgaard, Kristian. / Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. In: Neuropharmacology. 2019 ; Vol. 150. pp. 100-111.

Bibtex

@article{9e34591d235f4a4794f41129288b1d2b,
title = "Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor",
abstract = "Inhibition of postsynaptic density protein-95 (PSD-95) decouples N-methyl-d-aspartate (NMDA) receptor downstream signaling and results in neuroprotection after focal cerebral ischemia. We have previously developed UCCB01-144, a dimeric PSD-95 inhibitor, which binds PSD-95 with high affinity and is neuroprotective in experimental stroke. Here, we investigate the selectivity, efficacy and toxicity of UCCB01-144 and compare with the monomeric drug candidate Tat-NR2B9c. Fluorescence polarization using purified proteins and pull-downs of mouse brain lysates showed that UCCB01-144 potently binds all four PSD-95-like membrane-associated guanylate kinases (MAGUKs). In addition, UCCB01-144 affected NMDA receptor signaling pathways in ischemic brain tissue. UCCB01-144 reduced infarct size in young and aged male mice at various doses when administered 30 min after permanent middle cerebral artery occlusion, but UCCB01-144 was not effective in young male mice when administered 1 h post-ischemia or in female mice. Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. Overall, UCCB01-144 is a potent MAGUK inhibitor that reduces neurotoxic PSD-95-mediated signaling and improves neuronal survival following focal brain ischemia in rodents under various conditions and without causing cardiovascular side effects, which encourages further studies towards clinical stroke trials.",
author = "Anders Bach and Clausen, {Bettina H} and Kristensen, {Lotte K} and Andersen, {Maria G} and Ellman, {Ditte Gry} and Hansen, {Pernille B L} and Henrik Hasseldam and Marc Heitz and Dennis {\"O}zcelik and Tuck, {Ellie J} and Kopanitsa, {Maksym V} and Grant, {Seth G N} and Karin Lykke-Hartmann and Johansen, {Flemming F} and Lambertsen, {Kate L} and Kristian Str{\o}mgaard",
note = "Copyright {\circledC} 2019 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "3",
day = "2",
doi = "10.1016/j.neuropharm.2019.02.035",
language = "English",
volume = "150",
pages = "100--111",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor

AU - Bach, Anders

AU - Clausen, Bettina H

AU - Kristensen, Lotte K

AU - Andersen, Maria G

AU - Ellman, Ditte Gry

AU - Hansen, Pernille B L

AU - Hasseldam, Henrik

AU - Heitz, Marc

AU - Özcelik, Dennis

AU - Tuck, Ellie J

AU - Kopanitsa, Maksym V

AU - Grant, Seth G N

AU - Lykke-Hartmann, Karin

AU - Johansen, Flemming F

AU - Lambertsen, Kate L

AU - Strømgaard, Kristian

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2019/3/2

Y1 - 2019/3/2

N2 - Inhibition of postsynaptic density protein-95 (PSD-95) decouples N-methyl-d-aspartate (NMDA) receptor downstream signaling and results in neuroprotection after focal cerebral ischemia. We have previously developed UCCB01-144, a dimeric PSD-95 inhibitor, which binds PSD-95 with high affinity and is neuroprotective in experimental stroke. Here, we investigate the selectivity, efficacy and toxicity of UCCB01-144 and compare with the monomeric drug candidate Tat-NR2B9c. Fluorescence polarization using purified proteins and pull-downs of mouse brain lysates showed that UCCB01-144 potently binds all four PSD-95-like membrane-associated guanylate kinases (MAGUKs). In addition, UCCB01-144 affected NMDA receptor signaling pathways in ischemic brain tissue. UCCB01-144 reduced infarct size in young and aged male mice at various doses when administered 30 min after permanent middle cerebral artery occlusion, but UCCB01-144 was not effective in young male mice when administered 1 h post-ischemia or in female mice. Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. Overall, UCCB01-144 is a potent MAGUK inhibitor that reduces neurotoxic PSD-95-mediated signaling and improves neuronal survival following focal brain ischemia in rodents under various conditions and without causing cardiovascular side effects, which encourages further studies towards clinical stroke trials.

AB - Inhibition of postsynaptic density protein-95 (PSD-95) decouples N-methyl-d-aspartate (NMDA) receptor downstream signaling and results in neuroprotection after focal cerebral ischemia. We have previously developed UCCB01-144, a dimeric PSD-95 inhibitor, which binds PSD-95 with high affinity and is neuroprotective in experimental stroke. Here, we investigate the selectivity, efficacy and toxicity of UCCB01-144 and compare with the monomeric drug candidate Tat-NR2B9c. Fluorescence polarization using purified proteins and pull-downs of mouse brain lysates showed that UCCB01-144 potently binds all four PSD-95-like membrane-associated guanylate kinases (MAGUKs). In addition, UCCB01-144 affected NMDA receptor signaling pathways in ischemic brain tissue. UCCB01-144 reduced infarct size in young and aged male mice at various doses when administered 30 min after permanent middle cerebral artery occlusion, but UCCB01-144 was not effective in young male mice when administered 1 h post-ischemia or in female mice. Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. Overall, UCCB01-144 is a potent MAGUK inhibitor that reduces neurotoxic PSD-95-mediated signaling and improves neuronal survival following focal brain ischemia in rodents under various conditions and without causing cardiovascular side effects, which encourages further studies towards clinical stroke trials.

U2 - 10.1016/j.neuropharm.2019.02.035

DO - 10.1016/j.neuropharm.2019.02.035

M3 - Journal article

VL - 150

SP - 100

EP - 111

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -

ID: 216132830